“Pharmaceutical manufacturers face a growing array of new challenges in the market. Intense competition, rising commercialization costs, disaggregated data, consumerism and a shift to value-based care are key issues that complicate the commercialization process,” said Jim Cleary, Group President, Global Commercialization Services and Animal Health at AmerisourceBergen. “Fusion enables Lash Group to provide greater support to manufacturers. It powers more configurable and scalable patient support delivery, increases efficiency and provides a comprehensive set of services throughout the patient journey and product lifecycle.”
Developed in conjunction with a network of technology partnerships, Fusion helps manufacturers achieve meaningful business outcomes:
Accelerating Speed to Therapy: Fusion creates workflow efficiency, automates the decision-making process and streamlines administrative tasks, allowing for faster and more seamless access to treatment. Fusion leverages emerging technologies, such as artificial intelligence (AI) for benefit verification and multi-channel communication capabilities to remove common barriers to therapy.
Improving Patient and Provider Engagement: Patient and provider experience are important factors to the success of a product—the quality and level of service they receive impacts brand loyalty and trust. Combined with our highly talented and well-trained associates, Fusion technologies, like Computer-Telephony Integration, create a simpler, more intuitive set of interactions, allowing patients and providers to access the right information faster and receive a more personalized experience.
Generating Actionable Insights: Proving the value of a patient support program to both internal and external audiences is critical. Fusion generates actionable insights through strong quality data management, real-time reports and dashboards, targeted analytics available through mobile devices, competitive intelligence, and a more holistic view of the patient experience at a moment’s notice.
“There is no stronger example of AmerisourceBergen’s commitment to innovation and our ability to develop and deploy technologies that advance healthcare than Fusion,” said Dale Danilewitz, Chief Information Officer at AmerisourceBergen. “By combining Lash Group’s high-tech, smart-touch service model with dozens of proven tools and the company's deep expertise across life sciences, we’re producing a seamless, end-to-end experience for manufacturers, providers and most importantly, patients.”
With more than 20 years of experience and as the market leader in patient support services, Lash Group combines high-tech with smart touch to create and implement the most effective and efficient program delivery. Services include highly automated patient access and adherence programs based on a manufacturer’s needs and a patient-centric approach.
AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the pharmaceutical supply chain. Global manufacturers depend on us for services that drive commercial success for their products. Through our daily work—and powered by our 20,000 associates—we are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #11 on the Fortune 500, with more than $145 billion in annual revenue. The company is headquartered in Valley Forge, Pa. and has a presence in 50+ countries. Learn more at amerisourcebergen.com